Autolus Therapeutics plc (AUTL)
Automate Your Wheel Strategy on AUTL
With Tiblio's Option Bot, you can configure your own wheel strategy including AUTL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AUTL
- Rev/Share 0.0339
- Book/Share 1.3945
- PB 1.4773
- Debt/Equity 0.1555
- CurrentRatio 9.2438
- ROIC -0.3987
- MktCap 548244264.0
- FreeCF/Share -1.0666
- PFCF -1.9315
- PE -2.3022
- Debt/Assets 0.0773
- DivYield 0
- ROE -0.5282
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market
Published: June 06, 2025 by: Seeking Alpha
Sentiment: Positive
Autolus Therapeutics plc is a UK-based biotech that has brought its ex-vivo CAR-T cell therapy to market in B-ALL with a "best-in-class" safety/efficacy profile. In this small indication, peak revenues may be no more than $200 - $300m, but the drug's launch has been successful, with $9m earned in Q1 2025. Autolus plans to share more data from its FELIX study imminently, which could open up approval shots in other liquid cancer indications.
Read More
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Published: May 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-ALL
Read More
Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress
Published: May 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
LONDON, May 14, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of three abstracts submitted to the European Hematology Association (EHA) Congress, to be held June 12-15, 2025, Milan, Italy. Autolus will have two oral and one poster presentation, which includes updated follow up from the FELIX study of obecabtagene autoleucel (obe-cel) in adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL).
Read More
Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
LONDON, April 22, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its first quarter 2025 financial results and operational highlights before open of US markets on Thursday, May 8, 2025. Management will host a conference call and webcast at 8:30 am EDT/13:30 pm BST to discuss the company's financial results and provide a general business update.
Read More
Autolus Therapeutics plc (AUTL) Q4 2024 Earnings Conference Call Transcript
Published: March 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Autolus Therapeutics plc (NASDAQ:AUTL ) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Amanda Cray - IR Christian Itin - CEO Rob Dolski - CFO Conference Call Participants James Shin - Deutsche Bank Rajan Sharma - Goldman Sachs Asthika Goonewardene - Truist Matt Phipps - William Blair Gil Blum - Needham & Company Kelly Shi - Jefferies Yanan Zhu - Wells Fargo Jacob Mekhael - KBC Securities Simon Baker - Redburn Atlantic Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Call to Discuss the Full Year 2024 Financial Results and Business Updates. …
Read More
Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
AUCATZYL® (obecabtagene autoleucel) U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024 Obe-cel MHRA and EMA marketing authorizations expected in H2 2025 Initial six patients dosed in Phase 1 dose confirmation trial in Systemic Lupus Erythematosus (SLE) Company to provide clinical development program updates, including plans for expansion in autoimmune diseases, at R&D investor event to be held on April 23rd Conference call to be held today at 08:30 am EDT/12:30 pm GMT: conference call participants should pre-register using the link at the bottom of …
Read More
About Autolus Therapeutics plc (AUTL)
- IPO Date 2018-06-22
- Website https://www.autolus.com
- Industry Biotechnology
- CEO Dr. Christian Martin Itin Ph.D.
- Employees 647